Dyne Therapeutics, Inc.
NASDAQ:DYN
29.27 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 506 | 1,366 | 842 | 1,466 | 3 | 3 | 1,585 | 2,323 | 2,468 | 3,549 | 3,103 |
| Cost of Revenue
| 2.461 | 3.345 | 1.088 | 0.7 | 0.271 | 0.024 | 2,932 | 2,281 | 2,028 | 1,145 | 1,145 | 268 | 963 | 1,181 | 1,194 | 1,853 | 2,013 |
| Gross Profit
| -2.461 | -3.345 | -1.088 | -0.7 | -0.271 | -0.024 | -2,426 | -915 | -1,186 | 321 | -1,142 | -265 | 622 | 1,142 | 1,274 | 1,696 | 1,090 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -4.794 | -0.67 | -1.409 | 0.219 | -380.667 | -88.333 | 0.392 | 0.492 | 0.516 | 0.478 | 0.351 |
| Reseach & Development Expenses
| 210.762 | 142.76 | 121.308 | 45.2 | 11.04 | 4.278 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 31.4 | 28.202 | 28.717 | 13.447 | 2.786 | 0.517 | 189 | 161 | 128 | -97 | 97 | -22 | 135 | 163 | -159 | -157 | -203 |
| Selling & Marketing Expenses
| -2.461 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 31.4 | 28.202 | 28.717 | 13.447 | 2.786 | 0.517 | 189 | 161 | 128 | -97 | 97 | -22 | 135 | 163 | -159 | -157 | -203 |
| Other Expenses
| 0 | 2.863 | -0.008 | -0.79 | -1.323 | -0.021 | 0 | 0 | 0 | -211 | 0 | -59 | 0 | 0 | -360 | -337 | 0 |
| Operating Expenses
| 243.578 | 170.962 | 150.025 | 58.647 | 13.826 | 4.795 | 189 | 161 | 128 | -308 | 97 | -81 | 135 | 163 | -519 | -494 | -203 |
| Operating Income
| -242.162 | -170.962 | -150.025 | -58.647 | -13.826 | -4.795 | -412 | -640 | 64 | -318 | -318 | 714 | -236 | -11 | -834 | 709 | 605 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -0.814 | -0.469 | 0.076 | -0.217 | -106 | 238 | -0.149 | -0.005 | -0.338 | 0.2 | 0.195 |
| Total Other Income Expenses Net
| 6.225 | 2.863 | 0.734 | -0.79 | -1.033 | -0.021 | -126 | -649 | -491 | 50 | -99 | -627 | -2,041 | -224 | -521 | -463 | -338 |
| Income Before Tax
| -235.937 | -168.099 | -149.291 | -59.437 | -14.859 | -4.811 | -538 | -1,289 | -427 | -268 | -417 | 87 | -2,277 | -235 | -1,355 | 246 | 267 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -1.063 | -0.944 | -0.507 | -0.183 | -139 | 29 | -1.437 | -0.101 | -0.549 | 0.069 | 0.086 |
| Income Tax Expense
| 0 | -2.862 | -0.008 | -0.7 | -1.323 | -0.011 | -610 | -45 | -474 | 117 | -58 | -627 | -632 | 197 | 315 | -75 | -151 |
| Net Income
| -235.937 | -165.237 | -149.283 | -58.737 | -13.536 | -4.811 | 76 | -1,240 | 50 | -67 | -356 | 87 | -1,645 | -234 | -1,262 | 174 | 264 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.15 | -0.908 | 0.059 | -0.046 | -118.667 | 29 | -1.038 | -0.101 | -0.511 | 0.049 | 0.085 |
| EPS
| -3.95 | -3.18 | -2.93 | -4.08 | -0.3 | -0.47 | 0.47 | -9.61 | 0.4 | -0.53 | -3.56 | 0.87 | -13.48 | -1.95 | -1.25 | 0.2 | 0.15 |
| EPS Diluted
| -3.95 | -3.18 | -2.93 | -4.08 | -0.3 | -0.47 | 0.47 | -9.61 | 0.4 | -0.53 | -3.56 | 0.87 | -13.48 | -1.93 | -1.25 | 0.2 | 0.15 |
| EBITDA
| -240.489 | -170.962 | -148.203 | -58.647 | -14.588 | -4.787 | 949 | 106 | 736 | 292 | 150 | 113 | -1,574 | 734 | -173 | 902 | 830 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 1.875 | 0.078 | 0.874 | 0.199 | 50 | 37.667 | -0.993 | 0.316 | -0.07 | 0.254 | 0.267 |